ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN COMBINATION WITH GASTROESOPHAGEAL REFLUX DISEASE BEFORE AND AFTER ANTIREFLUX THERAPY

Liakh O. I., Tovt-Korshynska M. I., Derbak M. A., Lazorik M. I.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

There are currently limited data on the effectiveness of antireflux therapy in patients with COPD in combination with GERD.Therefore, it is promising to study the clinical effectiveness of comprehensive treatment of combined pathology. The criteria for the effectiveness of treatment in world medical practice are the duration and quality of life (QOL) of patients. The aim of the research to assess indicators of quality of life in patients with COPD with comorbid GERD before and after treatment. Materials and methods of the research. To study the effectiveness of antireflux therapy and its impact on the course of COPD, patients are divided into 2 groups: 1 group (main) (n=60) – patients with COPD in combination with GERD, group 2 – (control) – patients with isolated GERD. Groups of patients were representative by age and sex. Depending on the prescribed treatment, patients with a combination of COPD and GERD were divided into subgroups: 1-a (n=34) – against the background of basic therapy of COPD received antireflux therapy with rebamipide 100 mg 3 times a day for 1 month, and 1-b (n=26) – basic therapy of COPD in combination with antireflux without the use of rebamipide. All patients with positive Helicobacter pylori status (Hp +) received antihelicobacter therapy, which included amoxicillin 1000 mg, clarithromycin 500 mg, rabeprazole 20 mg – 1t. x 2 times a day from each drug – 14 days and probiotic Saccharomyces boulardii 1 capsule x 2 times a day – 10 days. Patients of subgroup 1-a on the background of basic therapy of COPD received antireflux therapy with rebamipide 100 mg 3 times a day for 1 month, and patients of subgroup 1-b – basic therapy of COPD in combination with antireflux without the use of rebamipide. Results. Against the background of therapy in patients of group 1-a, there was a positive dynamics of ERF (p>0.5). The increase in FEV1 was (8.2±0.1)%, which was better expressed than in patients of group 1-b, where this figure was respectively (4.2±0.2)%. Thus, the use of antireflux therapy improves the function of external respiration in patients with combined COPD and GERD. According to the results of the initial quality of life testing according to the GSRS questionnaire, after the treatment there was a significant improvement in the quality of life of patients compared with the data before treatment on all scales of symptoms. Evaluation of the results of the use of antireflux therapy by MO GERD-Q revealed a probable positive trend in the reduction of the score on the questionnaire at 1 week and 4 weeks after treatment. Conclusion. Thus, the complex treatment of combined pathology with the use of antireflux therapy has a positive effect not only on the clinical symptoms of the disease, but also on the indicators of external respiratory function and quality of life in patients with combined COPD and GERD.

quality of life, chronic obstructive pulmonary disease, antireflux therapy, rebamipide, combined course.

1. Mostovoy YuM, Slepchenko NS, Dmitriev KD, Sidorov AA. Hronichne obstruktivne zahvoryuvannya legen ta sertse: zdobutki ta pitannya sogodennya. Ukrayinskiy pulmonologIchniy zhurnal. 2018;4:56-61. [in Ukrainian].
2. Krahmalova OO, Shtorh VV, Getman OA, Kalashnik DM, Kolesnikova OM. Hronichne obstruktivne zahvoryuvannya legen i suputni patologichni stani. Osoblivosti porushen ritmu sertsya. Ukrayinskiy terapevtichniy zhurnal. 2016;2:119-123. [in Ukrainian].
3. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203(1):24-36.
4. Rubinsztajn R, Przybyłowski T, Grabicki M, Karwat K, Maskey Warzęchowska M, Batura-Gabryel H, et al. Comorbidities in chronic obstructive pulmonary disease: Results of a national multicenter research projekt. Adv Clin Exp Med. 2019;28(3):319-324.
5. Golpe R, Martín-Robles I, Sanjuán-López P, Cano-Jiménez E, Castro-Añon O, Mengual-Macenlle N, et al. Prevalence of major comorbidities in chronic obstructive pulmonary disease caused by biomass smoke or tobacco. Respiration. 2017;94(1):38-44.
6. Bobyk LR, Levynska NI, Piddubna AA, Vivsyannyk VV, Sazhyn NI. Metabolichni osoblyvosti erozyvno-vyrazkovykh urazhen shlunka ta dvanadtsyatypaloyi kyshky u khvorykh na khronichne obstruktyvne zakhvoryuvannya legen. Young Scientist. 2018;63(11):13-16. [in Ukrainian].
7. Gozhenko AI, Kovalevska LA, Kucher OV. KIiniko-patogenetichne obgruntuvannya kompleksnoyi terapiyi HOZL i suputnih gastropatiy. Aktualni problemi transportnoyi meditsini. 2013;3(33):88-94. [in Ukrainian].
8. Lin YH, Tsai CL, Tsao LI, Jeng C. Acute exacerbations of chronic obstructive pulmonary disease (COPD) experiences among COPD patients with comorbid gastrooesophageal reflux disease. Journal of clinical nursing. 2019;28(9-10):1925-1935.
9. Christensen S, Thomsen RW, Torring ML, Riis A, Norgaard M, Sorensen HT. Impact of COPD on outcome among patients with complicated peptic ulcer. Chest. 2008;133:1360-1366.
10. Hasegawa K, Sato S, Tanimura K, Fuseya Y, Uemasu K, Hamakawa Y, et al. Gastroesophageal reflux symptoms and nasal symptoms affect the severity of bronchitis symptoms in patients with chronic obstructive pulmonary disease. Respir Investig. 2018;56(3):230-237.
11. Shevchuk-Budz UI. The study of clinical and pathogenetic characteristics of the chronic bronchitis course on the background of the aggravating concomitant gastroesophageal reflux. The Pharma Innovation Journal 2018; 7(10):59-61. Available from: https://www.thepharmajournal.com/archives /2018/vol7issue 10/PartB/7-9-26-921.pdf .
12. Lee AL, Goldstein RS. Gastroesophageal reflux disease in COPD: links and risks. Int J Chron Obstruct Pulmon Dis. 2015;10:1935.
13. Kikuchi S, Imai H, Tani Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;(8):111-124.
14. Kuzmina GP, Lazarenko OM. Pokaznyky yakosti zhyttya ta funktsionalnogo statusu khvorykh na arterialnu gipertenziyu z komorbidnoyu podagroyu. Semeynaya medytsyna. 2019;(2):89-93. [in Ukrainian].
15. Shuper VO, Shuper SV, Rykova YuO, Trefanenko IV, Shumko GI. Optymizatsiya diagnostyky respiratornykh esktraezofagealnykh symptomiv gastroezofagealnoyi reflyuksnoyi khvoroby. Ukrayinskyy zhurnal medytsyny biologiyi ta sportu. 2019;4(5):249-255. [in Ukrainian].
16. Lebed KM. Otsinka yakosti zhyttya u khvorykh na khronichne obstruktyvne zakhvoryuvannya legen, spoluchene z nealkogolnym steatogepatytom. Problemy ekologichnoyi ta medychnoyi genetyky i klinichnoyi imunologiyi. 2011;(6):446-451. [in Ukrainian].

«Bulletin of problems biology and medicine» Issue 3 (161), 2021 year, 121-126 pages, index UDK 616.24-007.272:616/.33-002

10.29254/2077-4214-2021-3-161-121-126